JGC
ABBV icon

J. Goldman & Co’s AbbVie ABBV Stock Holding History

J. Goldman & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-178,591
Closed -$26M – 325
2023
Q3 		$26.6M Sell
178,591
-24,185
-12% -$3.55M 0.93% 29
2023
Q2 		$27.3M Buy
+202,776
New +$29.7M 0.99% 20
2022
Q4 		– Sell
-5,000
Closed -$671K – 358
2022
Q3 		$671K Buy
+5,000
New +$717K 0.03% 279

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

J. Goldman & Co's ABBV Position: Q4 2023 in Review

J. Goldman & Co sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 178,591 shares — an estimated $26M sold.

J. Goldman & Co first reported a position in ABBV in Q3 2022 and held it in 3 quarters. The position peaked at $27.3M in Q2 2023. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

  • J. Goldman & Co reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 178,591 AbbVie shares in Q4 2023, an estimated $26M.
  • J. Goldman & Co first reported a position in AbbVie in Q3 2022 and held it in 3 quarters.
  • J. Goldman & Co's AbbVie position peaked at $27.3M in Q2 2023.
  • 3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.